Drug intelligence / Profile preview

MY010

Development stage: Preclinical
Lead developer: Mabylon

Overview

MY010 is an early-stage drug candidate being developed by the Swiss biotech company Mabylon AG. It is intended for the treatment of birch-related allergies and is part of Mabylon's early-stage pipeline.

Targets

Bet v 1PR-10 (Pathogenesis-related protein family 10)

Beyond the preview

Go deeper on MY010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MY010.

Explore the full profile